Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The combination of INC280/buparlisib resulted in no clear activity in patients with recurrent PTEN-deficient glioblastoma.
|
31776899 |
2020 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Glioblastoma harbors frequent alterations in receptor tyrosine kinases, phosphatidylinositol‑3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) that dysregulate phospholipid signaling driven tumor proliferation and therapeutic resistance.
|
30942445 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We also identified protein signatures for GBMs with genetic alterations (IDH mutation, p53 mutation, EGFR amplification or mutation, CDKN2A/CDKN2B deletion, and PTEN mutation) that occur at high frequency.
|
30401645 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
|
31243804 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, miR-29a robustly promotes invasion in PTEN-deficient glioblastoma cells by repressing translation of the Sox4 transcription factor, and this upregulates the invasion-promoting protein, HIC5.
|
30683134 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to establish a radiomic signature to predict PTEN mutation status in patients with glioblastoma, and to investigate the genetic background behind this radiomic signature.
|
31218383 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Moreover, we found two genetic/clinical correlations that must be evaluated to understand their impact in the clinical setting: i) how is PTEN deletion a favorable prognostic factor in GBM IDH wildtype and an unfavorable prognostic factor in astrocytoma IDH wildtype and ii) how EGFR amplification is an independent and strong factor of response to radiotherapy.
|
31623593 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, neither PTEN nor EGFR mutation, which is frequently present in glioblastoma, was detected.
|
30496796 |
2019 |
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Analyses of human glioblastoma specimens reveals that PGK1 Y324 phosphorylation levels inversely correlate with PTEN expression status and are positively associated with poor prognosis in glioblastoma patients.
|
31492635 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) deficiency in primary human glioblastoma (GBM) is associated with increased invasiveness and poor prognosis with unknown mechanisms.
|
30357833 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genomic sequencing revealed that the spheroid lines contain alterations in GBM driver genes such as PTEN, CDKN2A, and NF1.
|
30289729 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Gain-of-function and loss-of-function studies indicated that PTEN enhanced the sensitivity of GBM cells to palbociclib <i>in vitro</i> and <i>in vivo</i>, which was associated with suppressions of Akt and ERK signaling and independent of Rb signaling inhibition.
|
31787897 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
NGI-1 sensitizes multiple models of GBM to chemotherapy and radiation <i>in vitro</i> and <i>in vivo</i> and may be especially effective in GBMs that retain active PTEN.<i>See related article by Baro et al., p. 784</i>.
|
30181388 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
2019;25:462-469) found that somatic PTEN mutations were associated with resistance to immune checkpoint inhibitors by altering immunosuppressive environments in patients with glioblastomas.
|
30928438 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Both PTEN-deficient (U-251) and PTEN-containing (LN229) glioblastoma cells showed a decrease in cell migration velocity in response to SKIP downregulation.
|
30695232 |
2019 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
GBM tumors with concurrent EGFR amplification and active phosphatase and tensin homolog (PTEN) are sensitive to the tyrosine kinase inhibitor erlotinib, but the effect is not durable.
|
31352310 |
2019 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
WITHDRAWAL: Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes.
|
29444555 |
2018 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We generated 3 PARPi-resistant PTEN-deficient glioblastoma U251 variants separately with olaparib (U251/OP), talazoparib (U251/TP) and simmiparib (U251/SP).
|
29274141 |
2018 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth.
|
29941984 |
2018 |
Glioblastoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
To identify transcriptomic profiles associated with a hyperactivated PI3K pathway, RNA-sequencing analysis was performed in a glioblastoma cell line stably expressing PTEN.
|
29729901 |
2018 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mitochondrial energy metabolism and signalling in human glioblastoma cell lines with different PTEN gene status.
|
29209894 |
2018 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
NQO1 Is Regulated by PTEN in Glioblastoma, Mediating Cell Proliferation and Oxidative Stress.
|
30595797 |
2018 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The phosphatase and tensin homolog (PTEN)/phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mTOR pathway has emerged as a crucial player in GBM development and progression.
|
30662577 |
2018 |
Glioblastoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Publisher Correction: PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3.
|
29799523 |
2018 |
Glioblastoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.
|
28464039 |
2017 |